What is AOD9604 (Fragment 176-191)?

AOD9604 is a synthetic peptide fragment of human growth hormone (hGH), corresponding to residues 176 through 191 of the full-length hormone; it is also written as hGH 176-191 and is described in the literature under the alternate expansion "Anti-Obesity Drug 9604" [2][3]. It belongs to the broader class of performance-enhancing peptides marketed as research compounds that are intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis, a group that also includes GHRH analogues such as sermorelin, tesamorelin and CJC-1295, and growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin and ipamorelin [1]. The evidence block supplied for this page does not give a residue sequence, molecular formula or molecular weight for the fragment, so none are stated here.

The work on this compound centres on the GH-IGF-1 axis and on peptide signalling networks that include PI3K/Akt, mTOR, MAPK, TGF-β and AMPK, the pathways through which therapeutic peptides are described as influencing tissue regeneration and cellular processes [6].

Where the material below is animal-only or in vitro, that is stated at the point of the finding. Where the evidence block does not support a claim, the claim is left out.

Research Studies

AOD9604 and its position among GH-IGF-1 axis research compounds

AOD9604 (hGH 176-191) is listed among the agents most commonly encountered in clinical practice and in online self-administration protocols within the GH-IGF-1 axis category, alongside GHRH analogues and growth hormone secretagogues [1]. That listing is a statement about which compounds appear in the field and in self-administration settings; it is not a statement about efficacy in any population.

The same review frames these agents collectively as performance-enhancing drugs marketed as "research compounds," and notes that they are unregulated peptides [1]. The classification matters for how the rest of the literature should be read: the category is defined by marketing and use patterns as much as by pharmacology.

AOD9604 and the "gray market" of unapproved peptides

A separate review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describes a parallel "gray market" of unapproved compounds operating largely outside regulatory oversight, emerging alongside peptides that have gone through a rigorous approval process evaluating both safety and efficacy [2][3]. AOD-9604 is named among the prominent unapproved peptides marketed direct to patients in that review [2][3].

The review's stated objective is to present pharmacological mechanisms, safety profiles and regulatory status for these compounds [2][3]. The evidence block does not supply the review's findings on AOD9604's mechanism or safety profile specifically, so those are not reported here.

AOD9604 and the peptide pharmacological niche

Peptides are described as short chains of amino acids occupying a pharmacological niche between small-molecule drugs and large proteins [2][3]. AOD9604 sits inside that definition by virtue of being a peptide fragment rather than a full-length protein or a small molecule.

That positioning is a structural and pharmacological description, not a claim about behaviour in any model. The evidence block does not provide comparative pharmacokinetic values for AOD9604 against small molecules or full-length proteins, so no such comparison is made here.

AOD9604 and peptide signalling pathways in orthopaedic research

Therapeutic peptides are described as emerging adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signalling networks central to cellular medicine [6]. The pathways named in that context are PI3K/Akt, mTOR, MAPK, TGF-β and AMPK, through which peptides are reported to exert influence over tissue regeneration [6].

This is a class-level statement about therapeutic peptides generally. The evidence block does not attribute a specific pathway result to AOD9604, and no such attribution is made here.

AOD9604 and detection in blood matrices

Analytical work on peptidic doping agents reports a fast, streamlined and harmonized workflow for detecting 54 prohibited substances in dried and liquid blood matrices [4]. The paper notes that previously published methods for detecting small peptides in dried blood spots typically involved multiple sample preparation steps, making them labor-intensive and costly [4].

This is method development and detection chemistry. It establishes that small peptides are analytically tractable in blood matrices; it does not report a biological effect of AOD9604 in any population.

AOD9604 and the regulatory status of marketed peptides

Across the reviews supplied, the recurring distinction is between peptides that have undergone a rigorous approval process evaluating safety and efficacy, and unapproved compounds marketed direct to patients outside regulatory oversight [2][3]. AOD-9604 is placed in the latter group [2][3].

The GH-IGF-1 axis review similarly characterises the agents it surveys, AOD9604 included, as unregulated peptides marketed as research compounds [1]. Neither review's regulatory framing should be read as a finding about biological activity.

AOD9604 and the limits of the supplied evidence

The evidence block for this page does not contain a primary study of AOD9604 in animals or in vitro, does not contain a human trial of the fragment, and does not contain a sequence, formula or molecular weight. What it contains is survey and review material placing the compound within the GH-IGF-1 axis category [1], within the unapproved "gray market" of peptides marketed direct to patients [2][3], within the general peptide pharmacological niche [2][3], within the class of peptides studied for signalling effects on PI3K/Akt, mTOR, MAPK, TGF-β and AMPK [6], and within the set of peptidic agents for which blood-matrix detection methods have been developed [4].

Any statement about what AOD9604 does in a particular tissue or model would require evidence this block does not provide. None is offered.

AOD9604 and how the category is described in the literature

The two review sources overlap in their framing: peptides occupy a niche between small molecules and large proteins, demand from patients for accelerated recovery and performance enhancement is driving expanded use in sports medicine, and a gray market of unapproved compounds has grown alongside the approved ones [2][3]. The GH-IGF-1 review adds that the agents in this space are encountered both in clinical practice and in online self-administration protocols [1].

These are descriptions of the field's composition and of how the compounds circulate. They are not outcome data.

Comparison of what the supplied sources cover

If you are reading this for personal health reasons

This material is sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. https://europepmc.org/article/PMC/PMC13322892
• [2] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://doi.org/10.20944/preprints202512.1011.v3
• [3] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://doi.org/10.20944/preprints202512.1011.v1
• [4] Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. https://pubmed.ncbi.nlm.nih.gov/42328738/
• [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://pubmed.ncbi.nlm.nih.gov/41966639/
• [6] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://europepmc.org/article/PMC/PMC12753158